Clinical trials: Antibody
Immunoglobulin G4-Related Disease, Janus Kinase Inhibitors
Tofacitinib in the Treatment of IgG4 Related Diseases
This study is a single centre, open label, randomized controlled study to compare the efficacy and safety between steroids plus tofacitinib and steroids alone in active IgG4-related diseases patients.
- Trial name
- NCT07827469
- Testing
- Tofacitinib 5mg Oral Tablet, Prednisone 5mg
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Peking University People's Hospital
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
TORCH-iTNT is a prospective, multicentre, randomized phase II trial. 198 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B (1:1).
- Trial name
- TORCH-iTNT (NCT06281405)
- Testing
- PD-1 inhibitor, Capecitabine, Short-course radiotherapy
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Fudan University
Cancer
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and ipilimumab in adult subjects with non-small cell lung cancer (NSCLC) or urothelial cancer to evaluate safety and efficacy.
- Trial name
- EMERGE (NCT03989362)
- Testing
- Vopratelimab, Ipilimumab
- Where
- 21 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Jounce Therapeutics, Inc.
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. This may be effective treatment for primary or metastatic brain tumors.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Neuroblastoma
- Trial name
- NCT00003461
- Testing
- surgical procedure, astatine At 211 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University
Non-Small Cell Lung Cancer
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
This study evaluated the efficacy and safety of tislelizumab in combination with platinum (cisplatin or carboplatin) and pemetrexed compared with platinum and pemetrexed alone as first-line treatment in participants with Stage…
- Trial name
- NCT03663205
- Testing
- Tislelizumab, Cisplatin, Carboplatin
- Where
- 47 sites in China
- Volunteers
- 334 people
- Sponsor
- BeiGene
Staphylococcus Aureus Bacteremia
Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.
This study is a Phase I/II, double-blind, placebo-controlled trial investigating the True Human monoclonal antibody 514G3 in subjects hospitalized with Staphylococcus aureus bacteremia.
- Trial name
- NCT02357966
- Testing
- 514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- XBiotech, Inc.
Rh Disease
Pharmacokinetics and Safety of Roledumab in RhD-negative Pregnant Women Carrying an RhD-positive Foetus
The aim of this study is to assess the pharmacokinetic profile of Roledumab 300μg IM / IV in RhD-negative pregnant women carrying an RhD-positive foetus.
- Trial name
- NCT02287896
- Testing
- ROLEDUMAB
- Where
- 8 sites in France
- Volunteers
- 62 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Covid-19
Correlation of Antibody Response to COVID-19 Vaccination in Pregnant Woman and Transplacental Passage Into Cord Blood.
The goal of this study is to study the correlation of maternal and cord blood level of Anti SAR-CoV.
- Trial name
- NCT06259656
- Testing
- COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)
- Where
- Thailand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vachira Phuket Hospital
Carcinoma, Non-Small-Cell Lung
Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease…
- Trial name
- NCT00034541
- Testing
- cetuximab, paclitaxel, carboplatin
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Bile Duct Obstruction, Extrahepatic
Clinical Validation of an Immunocytochemistry Method Using MARS1
The sensitivity of brushing cytology used to distinguish the cause of biliary strictures is low and clinical usefulness is not secured.
- Trial name
- MARS1 (NCT04759794)
- Testing
- Cytology staining
- Where
- 5 sites in South Korea
- Volunteers
- 55 people
- Sponsor
- Gangnam Severance Hospital
HIV-1-infection
Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV
This study is designed to evaluate the safety and efficacy of lefitolimod and 3BNC117/10-1074 in HIV-1-infected individuals on ART and during ATI as intervention to reduce the HIV-1 reservoir
- Trial name
- TITAN (NCT03837756)
- Testing
- Saline, Lefitolimod, 3BNC117 and 10-1074
- Where
- 8 sites in United States, Australia and 2 more
- Volunteers
- 47 people
- Sponsor
- University of Aarhus
Advanced Solid Tumours
A Study of EBC-129 in Advanced Solid Tumours
This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours
- Trial name
- NCT05701527
- Testing
- EBC-129, Pembrolizumab
- Where
- 5 sites in United States, Singapore and 1 more
- Volunteers
- 98 people
- Sponsor
- EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Multiple Myeloma, Myeloma
FT576 in Subjects With Multiple Myeloma
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
- Trial name
- NCT05182073
- Testing
- FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine
- Where
- 14 sites in United States
- Volunteers
- 31 people
- Sponsor
- Fate Therapeutics
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
MRI in Diagnosing and Monitoring CIDP
We want to study whether MRI can be useful in diagnosing and monitoring patients with CIDP in maintenance treatment with immunoglobulin
- Trial name
- NCT02017769
- Where
- Denmark
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Multiple Myeloma, AL Amyloidosis
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
The goal of this clinical trial is to learn if teclistamab in combination with daratumumab (Tec-Dara) works to treat newly diagnosed multiple myeloma with concurrent light chain amyloidosis (MM+AL).
- Trial name
- NCT07638683
- Testing
- Teclistamab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
ANCA-associated Vasculitis
MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS
Activation of neutrophils by ANCA ("Anti-Neutrophil Cytoplasm Antibodies") and subsequent microvascular endothelial cell damage is the main feature of ANCA-associated vasculitis (AAV), a severe autoimmune disease that often…
- Trial name
- MINERVA (NCT02954705)
- Testing
- Non interventional study
- Where
- France
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Pertussis
Pertussis Immunization During Pregnancy: Effect in Term and Preterm Infants
Young infants are most vulnerable to severe disease and even death when infected with Bordetella Pertussis. The current vaccines and vaccination programs do not guarantee protection of neonates.
- Trial name
- MAMA (NCT02511327)
- Testing
- Infant pertussis vaccination
- Where
- Belgium
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
This randomized pilot phase I trial studies the side effects and best dose of anti-SEMA4D monoclonal antibody VX15/2503 when given together with nivolumab or ipilimumab in treating patients with stage III or IV melanoma.
- Conditions
- Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7
- Trial name
- NCT03425461
- Testing
- Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Immunoglobulin Prophylaxis, Cytomegalovirus Infections
Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Human cytomegalovirus (CMV) is a globally prevalent, human-specific herpesvirus characterised by a lifelong latency after primary infection, an often asymptomatic reactivation and affecting up to 100% of adults based on region…
- Conditions
- Immunoglobulin Prophylaxis, Cytomegalovirus Infections, Allogeneic Hematopoietic Stem Cell Transplantation, Transplant-Related Disorder
- Trial name
- NCT07013370
- Testing
- Anti-CMV immunoglobulins [Megalotect (R)]
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Antonello Di Paolo, M.D., Ph.D.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.